Hikma Pharmaceuticals Plc - Company Profile
Powered by 
All the sales intelligence you need on Hikma Pharmaceuticals Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hikma Pharmaceuticals Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hikma Pharmaceuticals Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hikma Pharmaceuticals Plc (Hikma Pharmaceuticals) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones, and respiratory system, among others. It offers generics in various forms including tablets, capsules, solutions, and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments, and hospital purchasing organizations. The company markets its products in the UK, and North Africa (MENA) and Europe, the Middle East and Rest of the World. Hikma Pharmaceuticals is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
1 New Burlington Place, London, England, W1S2HR
Website
www.hikma.com
Telephone
44 20 73992760
No of Employees
9,603
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HIK (LON)
Revenue (2024)
$3.3B
6.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
12%
(2024 vs 2023)
Market Cap*
$4.4B
Net Profit Margin (2024)
XYZ
5.5%
(2024 vs 2023)
* As of and is in US$
Hikma Pharmaceuticals Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Injectables: | Amoclan |
| Fentanyl | Blopress |
| Glycopyrrolate | Cresemba |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company secured approval from the U.S. Food and Drug Administration (FDA) for Guardant360 Liquid CDx. |
| 2026 | Plans/Strategy | In June, the company announced its plans to expand its manufacturing operations in Ohio, the US. |
| 2026 | Contracts/Agreements | In May, the company and Marius Pharmaceuticals entered into a licensing agreement to commercialize KYZATREX (testosterone undecanoate) CIII capsules in Canada. |
Competitor Comparison
| Key Parameters | Hikma Pharmaceuticals Plc | Johnson & Johnson | Pfizer Inc | Novartis AG | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | Switzerland | United Kingdom |
| City | London | New Brunswick | New York City | Basel | London |
| State/Province | England | New Jersey | New York | Basel-Stadt | England |
| No. of Employees | 9,603 | 138,200 | 75,000 | 75,267 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Victoria Hull | Chairman | Executive Board | 2026 | 64 |
| Said Darwazah | Chief Executive Officer | Senior Management | 2025 | - |
| Hussein Arkhagha | Chief People Officer | Senior Management | 2023 | - |
| Khalid Nabilsi | Deputy Chief Executive Officer- North America and Europe | Senior Management | 2025 | - |
| Julie Hill | Senior Vice President - Corporate Quality Compliance/Health and Safety | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer